Protalix BioTherapeutics
PLX
36 hedge funds and large institutions have $4.63M invested in Protalix BioTherapeutics in 2017 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 11 reducing their positions, and 3 closing their positions.
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
6% more funds holding
Funds holding: 34 → 36 (+2)
0.32% less ownership
Funds ownership: 0.83% → 0.5% (-0.32%)
27% less capital invested
Capital invested by funds: $6.39M → $4.63M (-$1.75M)
45% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$1.23M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$76.8K |
| 3 |
CIBC Private Wealth Group
Atlanta,
Georgia
|
+$16.9K |
| 4 |
Bank of New York Mellon
New York
|
+$7.84K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$6.41K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
-$2.77M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$1.16M |
| 3 |
Renaissance Technologies
New York
|
-$72.7K |
| 4 |
BlackRock
New York
|
-$55K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$25K |
PLX Hedge Fund Activity: Q4 2017 in Review
36 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q4 2017, worth a combined $4.63M — down 27% from $6.39M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new PLX positions and 3 closed out — a net gain of 2 holders — while 6 added to existing stakes and 11 trimmed.
The largest buyer was Opaleye Management, opening a new position worth an estimated $1.23M. The largest seller was Highbridge Capital Management, cutting an estimated $2.77M.
- 36 institutional investors held Protalix BioTherapeutics (PLX) as of Q4 2017, up from 34 in Q3 2017.
- Funds reported $4.63M of Protalix BioTherapeutics stock for Q4 2017, down 27% quarter-over-quarter.
- 5 funds opened new Protalix BioTherapeutics positions in Q4 2017 and 3 closed out, a net change of +2 holders.
- The largest Protalix BioTherapeutics buyer in Q4 2017 was Opaleye Management, an estimated $1.23M added.
- The largest Protalix BioTherapeutics seller in Q4 2017 was Highbridge Capital Management, an estimated $2.77M sold.
Based on aggregated 13F filings for Q4 2017.